$USCTF
Roth CH Acquisition Co. Stock $usctf

$usctf Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000182912623002537 Filed on April 04, 2023

Income Statement

Concept	2022 Q4	2022
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.266M	$2.336M
YoY Change	-28.26%	28.53%
Operating Profit		-$2.336M
YoY Change
Interest Expense	$3.059M	$13.58M
YoY Change	-70.76%	29.82%
% of Operating Profit
Other Income/Expense, Net	$1.075M	$10.20M
YoY Change	-89.73%	-2.49%
Pretax Income	$1.793M	$11.25M
YoY Change	-79.38%	30.09%
Income Tax
% Of Pretax Income
Net Earnings	$1.793M	$11.25M
YoY Change	-79.38%	30.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.06	$0.39
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$124.2K	$124.2K
YoY Change	-99.95%	-83.45%
Cash & Equivalents	$124.2K
Short-Term Investments
Other Short-Term Assets	$336.1K	$336.1K
YoY Change	-19.36%	-19.36%
Inventory
Prepaid Expenses	$336.1K
Receivables
Other Receivables
Total Short-Term Assets	$460.3K	$460.3K
YoY Change	-60.57%	-60.57%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$238.0M	$238.0M
YoY Change	1.44%	1.44%
Other Assets	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$238.0M	$238.0M
YoY Change	1.3%	1.3%
TOTAL ASSETS
Total Short-Term Assets	$460.3K	$460.3K
Total Long-Term Assets	$238.0M	$238.0M
Total Assets	$238.4M	$238.4M
YoY Change	1.0%	1.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.582M	$1.582M
YoY Change	10291.85%	10291.85%
Accrued Expenses	$78.00K	$78.00K
YoY Change	-76.95%	-76.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.660M	$1.660M
YoY Change	369.27%	369.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.283M	$9.283M
YoY Change	-52.35%	-52.35%
Total Long-Term Liabilities	$9.283M	$9.283M
YoY Change	-52.35%	-52.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.660M	$1.660M
Total Long-Term Liabilities	$9.283M	$9.283M
Total Liabilities	$10.94M	$10.94M
YoY Change	-44.83%	-44.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.48M
YoY Change	-42.84%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.48M	$227.5M
YoY Change
Total Liabilities & Shareholders Equity	$238.4M	$238.4M
YoY Change	1.0%	1.0%

Cashflow Statement

Concept	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$1.793M	$11.25M
YoY Change	-79.38%	30.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$161.9K	-$606.2K
YoY Change	-80.68%	-27.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-$20.09K
YoY Change	-100.0%	-100.01%
NET CHANGE
Cash From Operating Activities	-161.9K	-$606.2K
Cash From Investing Activities	0.000
Cash From Financing Activities	0.000	-$20.09K
Net Change In Cash	-161.9K	-$626.3K
YoY Change	-121.57%	-183.45%
FREE CASH FLOW
Cash From Operating Activities	-$161.9K	-$606.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001860514
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity		usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet		usd
CY2022	USCTU	Increase Decrease In Accrued Offering Costs IncreaseDecreaseInAccruedOfferingCosts		usd
CY2022	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	USCTU	Payment Of Offering Costs PaymentOfOfferingCosts		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Sale Of Interest In Corporate Unit ProceedsFromSaleOfInterestInCorporateUnit		usd
CY2022	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2022	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties		usd
CY2022	USCTU	Deferredofferingcostsfrominitialpublicoffering Deferredofferingcostsfrominitialpublicoffering		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	USCTU	Other Other		usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2022	USCTU	Initial Classification Of Class Ordinary Shares Subject To Possible Redemption InitialClassificationOfClassOrdinarySharesSubjectToPossibleRedemption		usd
CY2022	USCTU	Initial Measurement Of Public Warrants And Private Placement Warrants InitialMeasurementOfPublicWarrantsAndPrivatePlacementWarrants		usd
CY2022	USCTU	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2022	USCTU	Deferred Offering Costs Included In Accrued Offering Costs DeferredOfferingCostsIncludedInAccruedOfferingCosts		usd
	USCTU	Deferred Offering Costs Included In Accrued Offering Costs DeferredOfferingCostsIncludedInAccruedOfferingCosts		usd
CY2022	USCTU	Deferred Offering Costs Paid By Sponsor For Class B Ordinary Shares DeferredOfferingCostsPaidBySponsorForClassBOrdinaryShares		usd
	USCTU	Deferred Offering Costs Paid By Sponsor For Class B Ordinary Shares DeferredOfferingCostsPaidBySponsorForClassBOrdinaryShares		usd
CY2022	USCTU	Deferred Offering Costs Paid By Sponsor Under Promissory Note DeferredOfferingCostsPaidBySponsorUnderPromissoryNote		usd
	USCTU	Deferred Offering Costs Paid By Sponsor Under Promissory Note DeferredOfferingCostsPaidBySponsorUnderPromissoryNote		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40959
CY2022	dei	Entity Registrant Name EntityRegistrantName	TKB CRITICAL TECHNOLOGIES 1
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1601095
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Continental Blvd
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	El Segundo
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90245
CY2022	dei	City Area Code CityAreaCode	310
CY2022	dei	Local Phone Number LocalPhoneNumber	426-2055
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	true
CY2022Q2	dei	Entity Public Float EntityPublicFloat	230460000	usd
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	New York
CY2022Q4	us-gaap	Cash Cash	124237	usd
CY2021Q4	us-gaap	Cash Cash	750562	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	336075	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	416760	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	460312	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1167322	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	237987827	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	234603942	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	322740	usd
CY2022Q4	us-gaap	Assets Assets	238448139	usd
CY2021Q4	us-gaap	Assets Assets	236094004	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1581635	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	42598	usd
CY2022Q4	USCTU	Accrued Offering Costs AccruedOfferingCosts	78000	usd
CY2021Q4	USCTU	Accrued Offering Costs AccruedOfferingCosts	311068	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1659635	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	353666	usd
CY2022Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	482825	usd
CY2021Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	10680000	usd
CY2022Q4	USCTU	Deferred Underwriter Fee Payable DeferredUnderwriterFeePayable	8800000	usd
CY2021Q4	USCTU	Deferred Underwriter Fee Payable DeferredUnderwriterFeePayable	8800000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10942460	usd
CY2021Q4	us-gaap	Liabilities Liabilities	19833666	usd
CY2022Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	237987827	usd
CY2021Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	234600000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10482723	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18340237	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10482148	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-18339662	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238448139	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	236094004	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2335719	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1817262	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2335719	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1817262	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10197175	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10457500	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	3383885	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	3752	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	198	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	13581060	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	10461450	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11245341	usd
	us-gaap	Net Income Loss NetIncomeLoss	8644188	usd
CY2022	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassOrdinaryShares	23000000	shares
	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassOrdinaryShares	5772549	shares
CY2022	USCTU	Basic And Diluted Net Income Per Share Class Ordinary Shares BasicAndDilutedNetIncomePerShareClassOrdinaryShares	0.39
	USCTU	Basic And Diluted Net Income Per Share Class Ordinary Shares BasicAndDilutedNetIncomePerShareClassOrdinaryShares	0.79
CY2022	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class B Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassBOrdinaryShares	5750000	shares
	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class B Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassBOrdinaryShares	5207843	shares
CY2022	USCTU	Basic And Diluted Net Income Per Share Class B Ordinary Shares BasicAndDilutedNetIncomePerShareClassBOrdinaryShares	0.39
	USCTU	Basic And Diluted Net Income Per Share Class B Ordinary Shares BasicAndDilutedNetIncomePerShareClassBOrdinaryShares	0.79
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
	USCTU	Deemed Capital Contribution From Sale Of Private Placement Warrants DeemedCapitalContributionFromSaleOfPrivatePlacementWarrants	537500	usd
	USCTU	Excess Fair Value Of Anchor Investor Shares ExcessFairValueOfAnchorInvestorShares	7748431	usd
	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-35299793	usd
	USCTU	Payments By Sponsor In Excess Of Promissory Note PaymentsBySponsorInExcessOfPromissoryNote	5012	usd
	us-gaap	Profit Loss ProfitLoss	8644188	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-18339662	usd
CY2022	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-3387827	usd
CY2022	us-gaap	Profit Loss ProfitLoss	11245341	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10482148	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11245341	usd
	us-gaap	Net Income Loss NetIncomeLoss	8644188	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	3383885	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	3752	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	198	usd
	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	-1365245	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10197175	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10457500	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-403425	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	739500	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1326054	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	42598	usd
	USCTU	Increase Decrease In Accrued Offering Costs IncreaseDecreaseInAccruedOfferingCosts	-311068	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-606240	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-837851	usd
	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments	234600000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-234600000	usd
CY2022	USCTU	Payment Of Offering Costs PaymentOfOfferingCosts	20085	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
	us-gaap	Proceeds From Sale Of Interest In Corporate Unit ProceedsFromSaleOfInterestInCorporateUnit	230000000	usd
	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	3850000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	10750000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	300000	usd
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	300000	usd
	USCTU	Deferredofferingcostsfrominitialpublicoffering Deferredofferingcostsfrominitialpublicoffering	-741607	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5012	usd
	USCTU	Other Other	8	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20085	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	236188413	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-626325	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	750562	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	750562	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124237	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	750562	usd
	USCTU	Initial Classification Of Class Ordinary Shares Subject To Possible Redemption InitialClassificationOfClassOrdinarySharesSubjectToPossibleRedemption	199300207	usd
	USCTU	Initial Measurement Of Public Warrants And Private Placement Warrants InitialMeasurementOfPublicWarrantsAndPrivatePlacementWarrants	21137500	usd
	USCTU	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	8800000	usd
CY2022	USCTU	Remeasurement Of Class Ordinary Shares Subject To Possible Redemption Amount RemeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionAmount	3387827	usd
	USCTU	Remeasurement Of Class Ordinary Shares Subject To Possible Redemption Amount RemeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionAmount	35299793	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_znx7rZMbvQua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_822_zRJtqk3sFyLa">Description of Organization and Business Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TKB Critical Technologies 1 (the “<span style="text-decoration: underline">Company</span>”) is a blank check company incorporated as a Cayman Islands exempted company on April 20, 2021. The Company was formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “<span style="text-decoration: underline">Business Combination</span>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not limited to a particular industry or geographic location for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company had not commenced any operations. All activity for the period from April 20, 2021 (inception) through December 31, 2022, relates to the Company’s formation and its initial public offering (the “<span style="text-decoration: underline">IPO</span>”), which is described below and, subsequent to the IPO, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of the Business Combination, at the earliest. The Company generates non-operating income from the marketable securities held in the Trust Account (defined below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registration statement for the Company’s IPO was declared effective on October 26, 2021 (the “<span style="text-decoration: underline">Effective Date</span>”). On October 29, 2021, the Company consummated the IPO of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd">23,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">units (the “<span style="text-decoration: underline">Units</span>”), including <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pdd">3,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units that were issued pursuant to the underwriters’ exercise of their over-allotment option in full, at $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd">10.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Unit, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0">230,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd">10,750,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Placement Warrants (the “<span style="text-decoration: underline">Private Placement Warrants</span>”) at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd">1.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Private Warrant in a private placement to TKB Sponsor I, LLC (the “<span style="text-decoration: underline">Sponsor</span>”), generating proceeds of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0">10,750,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs of the IPO amounted to $21,140,059, consisting of $3,850,000 of underwriting discount, $8,800,000 of deferred underwriting discount, $7,748,431 excess fair value of founder shares and $741,628 of offering costs. Of these amounts, $19,774,814 was recorded to additional paid-in capital and $1,365,245 costs related to the warrant liability was expensed immediately using the residual allocation method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the closing of the IPO on October 29, 2021, $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0">234,600,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd">10.20 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “<span style="text-decoration: underline">Trust Account</span>”), located in the United States, which will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination; and (ii) the redemption of any Public Shares (as defined below) properly submitted in connection with a shareholder vote to amend the Company’s amended and restated certificate of incorporation; and (iii) the redemption of the Company’s Public Shares if the Company is unable to complete the initial Business Combination within 15 months from October 29, 2021 (or any extended period of time that the Company may have to consummate an initial Business Combination as a result of an amendment to its Amended and Restated Memorandum and Articles of Association) (the “<span style="text-decoration: underline">Combination Period</span>”), the closing of the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete a Business Combination with one or more operating businesses or assets that together have an aggregate fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company’s signing a definitive agreement in connection with its initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target business or assets sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “<span style="text-decoration: underline">Investment Company Act</span>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will provide its holders of the outstanding Public Shares (the “<span style="text-decoration: underline">public shareholders</span>”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The public shareholder will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.20 per Public Share initially, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations and which interest shall be net of taxes payable), calculated as of two business days prior to the completion of the Business Combination. The per-share amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 8). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will only proceed with a Business Combination if the Company has net tangible assets of at least $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_c20220101__20221231_pp0p0">5,000,001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">either prior to or upon such consummation of a Business Combination and if the Company seeks shareholder approval. If the Company seeks shareholder approval, the Company will complete its Business Combination only if the Company receives approval pursuant to an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company, or (ii) if so authorized by the Company’s articles of association, a unanimous written resolution of the shareholders. If a shareholder vote is not required by applicable law or stock exchange rules and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “<span style="text-decoration: underline">SEC</span>”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange rules, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 6), and any Public Shares purchased during or after the IPO in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “<span style="text-decoration: underline">Exchange Act</span>”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Amended and Restated Certificate of Incorporation of the Company provides that only Public Shares and not any Founder Shares are entitled to redemption rights. In addition, the Sponsor has agreed (a) to waive its redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination and (b) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses, which interest shall be net of taxes payable), divided by the number of then-outstanding Public Shares, which redemption will completely extinguish public shareholders rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Cayman Islands law, to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire as worthless if the Company fails to complete a Business Combination within the Combination Period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriter has agreed to waive it right to its deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered (other than its independent registered public accounting firm) or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.20 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case, net of the interest which may be withdrawn to pay franchise and income taxes. This liability will not apply with respect to claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and will not apply as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “<span style="text-decoration: underline">Securities Act</span>”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As further described in Note 10, on January 10, 2023, the Company, entered into a business combination agreement with Wejo Group Limited, an exempted company limited by shares incorporated under the laws of Bermuda (“Wejo”), and Green Merger Subsidiary Limited, an exempted company incorporated under the laws of the Cayman Islands and a direct, wholly owned subsidiary of Wejo (“Merger Sub 1”) and upon execution of a joinder to the business combination agreement, each of Wejo Holdings Limited, an exempted company limited by shares incorporated under the laws of Bermuda and a wholly owned subsidiary of Wejo (“Holdco”) and Wejo Acquisition Company Limited, an exempted company limited by shares incorporated under the laws of Bermuda and a wholly owned Subsidiary of Holdco (“Merger Sub 2” and together with Merger Sub 1, the “Merger Subs”) (as it may be amended, restated, supplemented or otherwise modified from time to time, the “Business Combination Agreement”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity and Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company had $<span id="xdx_90B_eus-gaap--Cash_c20221231_pp0p0" title="Cash">124,237</span> cash and working capital deficit of $<span id="xdx_90F_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20221231_zldEijIOMTS9" title="Working capital deficit">1,199,323</span>. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company expects that it will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 27, 2023, the Company held an extraordinary general meeting (the “<span style="text-decoration: underline">Extraordinary General Meeting</span>”). At the Extraordinary General Meeting, the shareholders approved a proposal (the “<span style="text-decoration: underline">Extension Amendment Proposal</span>”) to amend the Company’s Amended and restated memorandum and articles of association (the “<span style="text-decoration: underline">Articles</span>”) to extend the date that the Company has to consummate a business combination from January 29, 2023 to June 29, 2023 (the “<span style="text-decoration: underline">Extension Amendment</span>”). The shareholders also approved a proposal (the “<span style="text-decoration: underline">Trust Agreement Amendment Proposal</span>”) to amend the Company’s Investment Management Trust Agreement, dated as of October 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company as trustee (the “<span style="text-decoration: underline">Trust Agreement</span>”), to make a corresponding extension to the date the Company must commence liquidation of the Trust Account from January 29, 2023 to June 29, 2023. In connection with the vote to approve the Extension Amendment Proposal, the holders of <span id="xdx_90A_ecustom--ExercisedShares_c20220101__20221231_z6Y38nZAsp1c" title="Exercised Shares">17,533,296 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.38 per share, for an aggregate redemption amount of approximately $<span id="xdx_907_ecustom--AggregateRedemptionAmount_iI_pn3n3_dm_c20221231_zxAa3VYkAjdl" title="Aggregate Redemption Amount">181.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Codification (“<span style="text-decoration: underline">ASC</span>”) Topic 205-40, “Basis of Presentation - Going Concern”. The Company has until June 29, 2023 (absent any extensions of such period by the Company’s shareholders) to consummate a Business Combination. While the Company intends to complete the proposed Business Combination before the mandatory liquidation date, it is uncertain that the Company will be able to consummate a Business Combination by that time. If a Business Combination is not consummated by that date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 29, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements does not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. The specific impact on the Company’s financial condition, results of operations and cash flows is also not determinable as of the date of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	5000001	usd
CY2022Q4	us-gaap	Cash Cash	124237	usd
CY2022Q4	USCTU	Working Capital Deficit WorkingCapitalDeficit	1199323	usd
CY2022	USCTU	Exercised Shares ExercisedShares	17533296	shares
CY2022Q4	USCTU	Aggregate Redemption Amount AggregateRedemptionAmount	181900000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zou4Xhlyq9nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zwyD3eyk5rEa">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Cash	124237	usd
CY2021Q4	us-gaap	Cash Cash	750562	usd
CY2021Q4	USCTU	Transaction Costs TransactionCosts	21140038	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	USCTU	Actual Offering Cost ActualOfferingCost	741607	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1365245	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19774793	usd
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_845_eus-gaap--DerivativesReportingOfDerivativeActivity_z4y65zvbbPR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z6AQan48O2J8">Derivative Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	USCTU	Remeasurement Amount RemeasurementAmount	35299793	usd
CY2022Q4	USCTU	Accumulated Deficit AccumulatedDeficit	27687038	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	USCTU	Deferred Legal Fees DeferredLegalFees	1164402	usd
	USCTU	Deferred Legal Fees DeferredLegalFees	212983	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zukJNstlNx94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zOfedtJUtz4a">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_909_eus-gaap--FederalFundsSold_c20221231_pp0p0" title="Federal Depository Insurance Coverage">250,000</span>. The Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Federal Funds Sold FederalFundsSold	250000	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	300000	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	279597	usd
CY2021Q4	USCTU	Notes Receivable Related Partie NotesReceivableRelatedPartie	20403	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	100000	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	20000	usd
CY2022	USCTU	Related Party Loans Description RelatedPartyLoansDescription	The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant.
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022	USCTU	Share Redemption Price Per Share ShareRedemptionPricePerShare	18.00
CY2021Q4	USCTU	Cash Underwriting Discount CashUnderwritingDiscount	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Commissions DeferredUnderwritingCommissions	8800000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	350000	usd
CY2022	us-gaap	Acquisition Costs AcquisitionCosts	1000000	usd
CY2022Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1000000	usd
CY2022Q3	USCTU	Other Fees OtherFees	100000	usd
CY2022	us-gaap	Sponsor Fees SponsorFees	191402	usd
CY2021Q4	USCTU	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	42181	usd
CY2022Q4	USCTU	Fair Value Price Per Warrant FairValuePricePerWarrant	0.02
CY2021Q4	USCTU	Fair Value Price Per Warrant FairValuePricePerWarrant	0.48
CY2022	USCTU	Fair Value Measurement FairValueMeasurement	5520000	usd

Files In Submission

Name	View Source	Status
0001829126-23-002537-index-headers.html	Edgar Link	pending
0001829126-23-002537-index.html	Edgar Link	pending
0001829126-23-002537.txt	Edgar Link	pending
0001829126-23-002537-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tkbcriticaltech1_10k.htm	Edgar Link	pending
tkbcriticaltech1_ex31-1.htm	Edgar Link	pending
tkbcriticaltech1_ex31-2.htm	Edgar Link	pending
tkbcriticaltech1_ex32-1.htm	Edgar Link	pending
tkbcriticaltech1_10k_htm.xml	Edgar Link	completed
tkbcriticaltech1_ex32-2.htm	Edgar Link	pending
tkbcriticaltech1_ex4-5.htm	Edgar Link	pending
usctu-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
usctu-20221231_def.xml	Edgar Link	unprocessable
usctu-20221231_lab.xml	Edgar Link	unprocessable
usctu-20221231_pre.xml	Edgar Link	unprocessable
usctu-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USCTF
Roth CH Acquisition Co. Stock $usctf

2022 Q4 Form 10-K Financial Statement

#000182912623002537 Filed on April 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USCTF Roth CH Acquisition Co. Stock $usctf

2022 Q4 Form 10-K Financial Statement

#000182912623002537 Filed on April 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USCTF
Roth CH Acquisition Co. Stock $usctf